Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MTX · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | OTHER | Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX |
| MTX | DRUG | Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week |
| Infliximab | BIOLOGICAL | Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX |
Inclusion Criteria: * Diagnosis of RA according to the revised 1987 criteria of the American Rheumatism Association (Arnett et al, 1988). The disease should have been diagnosed at least 6 months prior to screening. * Active disease at the time of screening and pre-infusion as defined by: * \>=6 ...
MTX is a small molecule being studied for the treatment of rheumatoid arthritis. It is currently in Phase 3 clinical development as an investigational therapy for this condition. The drug is being evaluated in patients with rheumatoid arthritis who have not responded adequately to other treatments.
MTX is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the safety and efficacy of MTX in patients with rheumatoid arthritis.
MTX is currently in Phase 3 clinical development for the treatment of rheumatoid arthritis. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the data are being analyzed to determine the drug's safety and efficacy profile.
MTX has been studied in one completed Phase 3 clinical trial, identified as NCT00202852. This trial was a placebo-controlled, double-blinded, randomized study that enrolled 143 patients with rheumatoid arthritis who were also taking methotrexate. The trial was conducted in South Korea and included adult patients aged 18 years and older.
MTX is not the same as Remicade. The clinical trial NCT00202852 evaluated the combination of Remicade and methotrexate in patients with rheumatoid arthritis. MTX refers to methotrexate, which is a standard treatment for rheumatoid arthritis, while Remicade is a separate biologic drug. The trial studied the effects of adding Remicade to methotrexate therapy.